Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) and Tasso, Inc. have announced a joint venture to distribute Tasso’s on-demand blood collection device in Japan. This collaboration aims to enhance self-medication, preventative medicine, and telemedicine in Japan, potentially reducing the burden on medical professionals. While the joint venture’s immediate impact on SNBL’s business performance is minor, it is expected to expand the company’s presence in telemedicine over the medium to long term.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) operates in the biomedical industry, focusing on contract research and translational research services. The company is known for its strong network in the United States and Japan, facilitating collaborations between academia, investors, and professional companies.
YTD Price Performance: -9.17%
Average Trading Volume: 300,490
Technical Sentiment Signal: Hold
Current Market Cap: Yen62.99B
For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.